1C. H. Pui, J. J. Yang, S. P. Hunger, et al., “Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration,” Journal of Clinical Oncology 33, no. 27 (September 20, 2015): 2938–2948, https://doi.org/10.1200/jco.2014.59.1636.
10.1200/JCO.2014.59.1636
CAS PubMed Web of Science® Google Scholar
2H. J. Müller and J. Boos, “Use of L-asparaginase in Childhood ALL,” Critical Reviews in Oncology 28, no. 2 (August 1998): 97–113, https://pubmed.ncbi.nlm.nih.gov/9768345/.
10.1016/S1040-8428(98)00015-8
CAS PubMed Web of Science® Google Scholar
3J. Boos, “Pharmacokinetics and Drug Monitoring of L-Asparaginase Treatment,” International Journal of Clinical Pharmacology & Therapeutics 35, no. 3 (March 1, 1997): 96–98, https://europepmc.org/article/med/9088996.
CAS PubMed Google Scholar
4D. Hammond, M. H. Donaldson, R. E. Hittle, and M. Karon, “L-Asparaginase, Vincristine, and Prednisone for Induction of First Remission in Acute Lymphocytic Leukemia,” Cancer Research 37, no. 2 (1977): 535–540, https://pubmed.ncbi.nlm.nih.gov/264412/.
PubMed Google Scholar
5S. E. Sallan, S. Hitchcock-Bryan, R. Gelber, J. R. Cassady, E. F. Iii, and D. G. Nathan, “Influence of Intensive Asparaginase in the Treatment of Childhood Non-T-cell Acute Lymphoblastic Leukemia1,” Cancer Research 43 (1983), http://aacrjournals.org/cancerres/article-pdf/43/11/5601/2415095/cr0430115601.pdf.
Google Scholar
6M. D. Amylon, J. Shuster, J. Pullen, et al., “Intensive High-Dose Asparaginase Consolidation Improves Survival for Pediatric Patients With T Cell Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Lymphoma: A Pediatric Oncology Group Study,” Leukemia 13, no. 3 (1999): 335–342, https://doi.org/10.1038/sj.leu.2401310.
10.1038/sj.leu.2401310
CAS PubMed Web of Science® Google Scholar
7L. B. Silverman, R. D. Gelber, V. K. Dalton, et al., “Improved Outcome for Children With Acute Lymphoblastic Leukemia: Results of Dana-Farber Consortium Protocol 91-01,” Blood 97, no. 5 (March 1, 2001): 1211–1218, https://doi.org/10.1182/blood.v97.5.1211.
10.1182/blood.V97.5.1211
CAS PubMed Web of Science® Google Scholar
8J. B. Nachman, H. N. Sather, M. G. Sensel, et al., “Augmented Post-Induction Therapy for Children With High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy,” New England Journal of Medicine 338, no. 23 (June 4, 1998): 1663–1671, https://doi.org/10.1056/nejm199806043382304.
10.1056/NEJM199806043382304
CAS PubMed Web of Science® Google Scholar
9N. L. Seibel, P. G. Steinherz, H. N. Sather, et al., “Early Postinduction Intensification Therapy Improves Survival for Children and Adolescents With High-Risk Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group,” Blood 111, no. 5 (March 1, 2008): 2548–2555, https://doi.org/10.1182/blood-2007-02-070342.
10.1182/blood-2007-02-070342
CAS PubMed Web of Science® Google Scholar
10B. K. Albertsen, K. Grell, J. Abrahamsson, et al., “Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study,” Journal of Clinical Oncology 37, no. 19 (2019): 1638–1646, https://doi.org/10.1200/jco.18.01877.
10.1200/JCO.18.01877
CAS PubMed Web of Science® Google Scholar
11M. Campbell, C. Kiss, M. Zimmermann, et al., “Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial,” Journal of Clinical Oncology 41, no. 19 (July 1, 2023): 3499–3511, https://doi.org/10.1200/jco.22.01760.
10.1200/JCO.22.01760
CAS PubMed Google Scholar
12V. Conter, M. G. Valsecchi, G. Cario, et al., “Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study,” Journal of Clinical Oncology 42, no. 8 (March 10, 2024): 915–926, https://doi.org/10.1200/jco.23.01388.
10.1200/JCO.23.01388
CAS PubMed Google Scholar
13M. Kato, Y. Okamoto, T. Imamura, et al., “JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL,” Journal of Clinical Oncology (November 12, 2024), https://pubmed.ncbi.nlm.nih.gov/39531610/.
10.1200/JCO.24.00811
Google Scholar
14S. Gupta, C. Wang, E. A. Raetz, et al., “Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group,” Journal of Clinical Oncology 38, no. 17 (April 10, 2020): 1897–1905, https://doi.org/10.1200/jco.19.03024.
10.1200/JCO.19.03024
CAS PubMed Web of Science® Google Scholar
15I. M. Van Der Sluis, L. J. Brigitha, M. Fiocco, et al., “Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial,” Journal of Clinical Oncology 42, no. 14 (May 10, 2024): 1676–1686, https://doi.org/10.1200/jco.23.01797.
10.1200/JCO.23.01797
CAS PubMed Google Scholar

Volume43, Issue1

January 2025

e70032

Childhood ALL and Asparaginase Intensification: Are We at the Brink?

Open Research

Peer Review

Data Availability Statement

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Childhood ALL and Asparaginase Intensification: Are We at the Brink?

Open Research

Peer Review

Data Availability Statement

References

References

Related

Information